Clinical study on Jinfukang Oral Liquid combined with chemotherapy in the treatment of non⁃small cell lung cancer at Ⅰb⁃Ⅱb stages after operation based on circulating tumor cell

Enhao LU; Yilin YAO; Hegen LI; Lihua ZHU; Lei ZHOU; Rui FAN; Yiran OUYANG; Ren ZHANG; Hechuan TIAN

doi:10.16306/j.1008-861x.2022.04.005

您当前的位置：

首页 >

文章列表页 >

Clinical study on Jinfukang Oral Liquid combined with chemotherapy in the treatment of non⁃small cell lung cancer at Ⅰb⁃Ⅱb stages after operation based on circulating tumor cell

Clinical Research | 更新时间：2022-08-29

- Clinical study on Jinfukang Oral Liquid combined with chemotherapy in the treatment of non⁃small cell lung cancer at Ⅰb⁃Ⅱb stages after operation based on circulating tumor cell
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 36, Issue 4, Pages: 31-35(2022)
- 作者机构：
  
  1.上海中医药大学附属龙华医院肿瘤科（上海　200032）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2022.04.005
  CLC：
扫描看全文
陆恩昊,姚逸临,李和根等.基于循环肿瘤细胞金复康口服液联合化疗治疗术后Ⅰb~Ⅱb期非小细胞肺癌的临床研究[J].上海中医药大学学报,2022,36(04):31-35.

LU Enhao,YAO Yilin,LI Hegen,et al.Clinical study on Jinfukang Oral Liquid combined with chemotherapy in the treatment of non⁃small cell lung cancer at Ⅰb⁃Ⅱb stages after operation based on circulating tumor cell[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(04):31-35.
陆恩昊,姚逸临,李和根等.基于循环肿瘤细胞金复康口服液联合化疗治疗术后Ⅰb~Ⅱb期非小细胞肺癌的临床研究[J].上海中医药大学学报,2022,36(04):31-35. DOI： 10.16306/j.1008-861x.2022.04.005.

LU Enhao,YAO Yilin,LI Hegen,et al.Clinical study on Jinfukang Oral Liquid combined with chemotherapy in the treatment of non⁃small cell lung cancer at Ⅰb⁃Ⅱb stages after operation based on circulating tumor cell[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2022,36(04):31-35. DOI： 10.16306/j.1008-861x.2022.04.005.

摘要

目的,2,基于循环肿瘤细胞（CTC）比较单纯化疗与金复康口服液联合化疗治疗Ⅰb～Ⅱb期非小细胞肺癌（NSCLC）术后患者的疗效差异。,方法,2,采用多中心随机对照研究方法，纳入144例Ⅰb～Ⅱb期NSCLC术后患者，随机分为治疗组72例与对照组72例，对照组患者给予含铂双药化疗方案治疗，治疗组患者在对照组治疗基础上给予金复康口服液口服。21~28 d为1个化疗周期，共治疗4个周期。分别于化疗前、化疗中（第2周期化疗后）、化疗后（第4周期化疗后）及化疗结束后1年、1.5年、2年，检测所有患者的CTC计数，并于化疗前检测所有患者的肿瘤标志物及免疫指标水平。采用重复测量分析探讨CTC变化趋势，采用Spearman分析法对CTC计数与肿瘤标志物、免疫指标水平进行相关性分析，采用多因素线性回归对CTC计数与免疫指标水平进行相关性分析。,结果,2,研究中，3例患者被剔除，最终纳入统计分析者治疗组70例、对照组71例。①对照组患者的CTC计数在化疗期间下降，但在化疗结束后出现反弹，治疗组患者的CTC计数在化疗中及化疗后均持续下降，无反弹趋势。②Ⅱb期患者化疗结束后1年CTC计数治疗组低于对照组（,P,<,0.05），其他观察时点组间差异均无统计学意义（,P,>,0.05）。③相关性分析结果显示，CTC计数与癌胚抗原（CEA）、CD8,+,T淋巴细胞水平呈正相关（,P,<,0.05）。,结论,2,金复康口服液联合化疗可在一定程度上降低Ⅰb～Ⅱb期NSCLC术后患者外周血CTC计数，并在一定程度上抑制化疗结束后CTC计数的反弹趋势，尤其对Ⅱb期患者效果更显著。

Abstract

Objective： To compare the curative effect between chemotherapy and Jinfukang Oral Liquid combined with chemotherapy in treating postoperative patients with non-small cell lung cancer （NSCLC） at Ⅰb-Ⅱb stages based on circulating tumor cell （CTC）.,Methods,2,A multi-center randomized controlled trial was applied. A total of 144 postoperative patients with NSCLC at Ⅰb-Ⅱb stages were included and randomly divided into the treatment group （72 cases） and control group （72 cases）. The patients in the control group were treated with platinum-containing double-drug chemotherapy， and the patients in the treatment group were orally treated with Jinfukang Oral Liquid based on the treatment of the control group. 21~28 days were one chemotherapy cycle and a total of 4 cycles were done. Before chemotherapy， in the middle of chemotherapy （after two chemotherapy cycles）， after chemotherapy （after four chemotherapy cycles）， and 1， 1.5 and 2 years after chemotherapy， the CTC count of all patients was detected， and the levels of tumor marker and immunological indicators were tested before chemotherapy. The changing trend of CTC was explored by repeated measurement analysis， the correlation between CTC count and the levels of tumor marker and immunological indicators was analyzed by Spearman analysis method， and the correlation between CTC count and the levels of immunological indicators was analyzed by multiple linear regression.,Results,2,In the study， 3 patients were eliminated， and finally 70 cases in the treatment group and 71 cases in the control group were included in the statistical analysis. ①The CTC count of the control group decreased during chemotherapy， but rebounded after chemotherapy， and the CTC count of the treatment group decreased continuously in the middle of chemotherapy and after chemotherapy with no rebound trend. ②One year after chemotherapy， the CTC count of the patients at Ⅱb stage in the treatment group was lower than that in the control group （,P,<,0.05）， and there were no statistical differences in other time points （,P,>,0.05）. ③The results of correlation analysis showed that， there was a positive correlation between CTC count and the levels of carcinoembryonic antigen （CEA） and CD8,+ ,T lymphocyte （,P,<,0.05）.,Conclusion,2,Jinfukang Oral Liquid combined with chemotherapy can decrease the peripheral blood CTC count to a certain degree in treating postoperative patients with NSCLC at Ⅰb-Ⅱb stages， and inhibit the rebound trend of CTC count after chemotherapy to a certain degree， especially for the patients at Ⅱb stage.

关键词

非小细胞肺癌术后金复康口服液化疗循环肿瘤细胞

Keywords

non-small cell lung cancerafter operationJinfukang Oral Liquidchemotherapycirculating tumor cell

references

SIEGE R L， MILLER K D， JEMAL A. Cancer statistics， 2019［J］ .CA Cancer J Clin， 2019， 69（1）： 7-34.

ALLEMANI C， MATSUDA T， DI CARLO V， et al. Global surveillance of trends in cancer survival 2000-14（CONCORD-3）： analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries［J］. Lancet， 2018， 391（10125）： 1023-1075.

中华医学会呼吸病学分会肺癌学组，中国肺癌防治联盟. 晚期非小细胞肺癌分子靶向治疗专家共识（2013版）［J］. 中华结核和呼吸杂志， 2014， 37（3）： 177-183.

王泽洲，张扬，莫淼，等. 大型单中心医院登记的7 753例肺癌手术患者生存报告：基于第8版国际肺癌TNM分期标准［J］. 中国癌症杂志， 2020， 30（5）： 321-327.

杨迎庆，蒋幼凡. 非小细胞肺癌的二线治疗进展［J］. 现代医药卫生， 2016， 32（13）： 2027-2030.

HUNG J J， JENG W J， HSU W H， et al. Prognostic factors of postrecurrence survival in completely resected stageⅠnon-small cell lung cancer with distant metastasis［J］. Thorax， 2010， 65（3）： 241-245.

MAEDA R， YOSHIDA J， ISHII G， et al. Long-term outcome and late recurrence in patients with completely resected stage ⅠA non-small cell lung cancer［J］. J Thorac Oncol， 2010， 5（8）：1246-1250.

韦伟，谢家政. 非小细胞肺癌的非手术治疗新进展［J］. 承德医学院学报， 2014， 31（6）： 520-523.

PLAKS V， KOOPMAN C D， WERB Z. Circulating tumor cells［J］. Science， 2013， 341（6151）： 1186-1188.

HASHIMOTO M， TANAKA F， YONEDA K， et al. Positive correlation between postoperative tumor recurrence and changes in circulating tumor cell counts in pulmonary venous blood （pvCTC） during surgical manipulation in non-small cell lung cancer［J］. J Thorac Dis， 2018， 10（1）： 298-306.

TANAKA F， YONEDA K， KONDO N， et al. Circulating tumor cell as a diagnostic marker in primary lung cancer［J］. Clin Cancer Res， 2009， 15（22）： 6980-6986.

MALY V， MALY O， KOLOSTOVA K， et al. Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer［J］. In Vivo， 2019， 33（4）： 1027-1037.

刘嘉湘，施志明，徐振晔，等. 滋阴生津益气温阳法治疗晚期原发性肺腺癌的临床研究［J］. 中医杂志，1995， 36（3）： 155-158.

刘嘉湘，施志明，李和根，等. 益肺抗瘤饮治疗271例非小细胞肺癌临床观察［J］. 上海中医药杂志， 2001， 35（2）： 4-6.

毕凌，金莎，郑展，等. 肺积方对IDO诱导Lewis肺癌小鼠模型免疫逃逸的影响［J］. 中国中西医结合杂志， 2016， 36（1）： 69-74.

田建辉，杨晓霞，毕凌，等. 金复康对免疫衰老小鼠肺癌移植瘤的防治作用［J］. 中国肿瘤生物治疗杂志， 2016， 23（1）： 36-43.

徐蔚杰，李春杰，刘嘉湘，等. 金复康口服液抑制Lewis肺癌Sca-1+干细胞亚群增殖的研究［J］. 上海中医药杂志， 2015， 49（1）： 69-71， 86.

中国抗癌协会. 新编常见恶性肿瘤诊治规范［M］. 北京：北京医科大学中国协和医科大学联合出版社， 1998.

中国临床肿瘤学会指南工作委员会. 原发性肺癌诊疗指南［M］. 北京：人民卫生出版社， 2017.

上海市卫生局. 上海市中医病证诊疗常规［M］. 上海：上海中医药大学出版社， 2003.

MULEY T， FETZ T H， DIENEMANN H， et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC［J］. Lung Cancer， 2008， 60（3）： 408-415.

GRUNNET M， SORENSEN J B. Carcinoembryonic antigen （CEA） as tumor marker in lung cancer［J］. Lung Cancer， 2012， 76（2）： 138-143.

董昌盛，阙祖俊，朱丽华，等. 基于循环肿瘤细胞的非小细胞肺癌之“伏毒”本质临证探析［J］. 上海中医药大学学报， 2018， 32（1）： 18-22.

Views

157

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical study of Chinese medicine combined with adjuvant chemotherapy on patients with non-small cell lung cancer at stage Ⅲa after complete resection

Clinical study on essence of “hidden toxin” in non-small cell lung cancer based on circulating tumor cell expression

Analysis on Related Prognostic Factors of Disease Free Survival for Patients with Non-small Cell Lung Cancer at Stage Ⅲa after Complete Resection

“Xiakucao Xiaoliu Mixture” Combined with Chemotherapy in Treating Patients with Advanced Non-small Cell Lung Cancer:A Report of 30 Cases

Research progress on mechanisms of m⁶A RNA methylated modification regulating non⁃small cell lung cancer

Related Author

No data

Related Institution

Third Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University

Oncology Institute of Chinese Medicine,Shanghai Academy of Traditional Chinese Medicine

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology,Municipal Hospital of Integrated Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

⁰